ATE482210T1 - Oxadiazolderivate als s1p1-rezeptor-agonisten - Google Patents

Oxadiazolderivate als s1p1-rezeptor-agonisten

Info

Publication number
ATE482210T1
ATE482210T1 AT07857804T AT07857804T ATE482210T1 AT E482210 T1 ATE482210 T1 AT E482210T1 AT 07857804 T AT07857804 T AT 07857804T AT 07857804 T AT07857804 T AT 07857804T AT E482210 T1 ATE482210 T1 AT E482210T1
Authority
AT
Austria
Prior art keywords
receptor agonists
oxadiazole derivatives
formula
treatment
pharmaceutical compositions
Prior art date
Application number
AT07857804T
Other languages
English (en)
Inventor
Mahmood Ahmed
James Myatt
David Norton
Dean Andrew Rivers
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE482210T1 publication Critical patent/ATE482210T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AT07857804T 2006-12-21 2007-12-19 Oxadiazolderivate als s1p1-rezeptor-agonisten ATE482210T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0625648.1A GB0625648D0 (en) 2006-12-21 2006-12-21 Compounds
PCT/EP2007/064181 WO2008074820A1 (en) 2006-12-21 2007-12-19 Oxadiazole derivatives as s1p1 receptor agonists

Publications (1)

Publication Number Publication Date
ATE482210T1 true ATE482210T1 (de) 2010-10-15

Family

ID=37734705

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07857804T ATE482210T1 (de) 2006-12-21 2007-12-19 Oxadiazolderivate als s1p1-rezeptor-agonisten

Country Status (7)

Country Link
US (1) US20100048639A1 (de)
EP (1) EP2091950B1 (de)
AT (1) ATE482210T1 (de)
DE (1) DE602007009420D1 (de)
ES (1) ES2352859T3 (de)
GB (1) GB0625648D0 (de)
WO (1) WO2008074820A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8580841B2 (en) 2008-07-23 2013-11-12 Arena Pharmaceuticals, Inc. Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders
HRP20160890T1 (hr) 2008-08-27 2016-09-23 Arena Pharmaceuticals, Inc. Derivati supstituirane tricikličke kiseline kao agonisti s1p1-receptora korisni u liječenju autoimunih i upalnih poremećaja
WO2010085582A1 (en) 2009-01-23 2010-07-29 Bristol-Myers Squibb Company Substituted oxadiazole derivatives as s1p agonists in the treatment of autoimmune and inflammatory diseases
JP2012515787A (ja) 2009-01-23 2012-07-12 ブリストル−マイヤーズ スクイブ カンパニー 自己免疫疾患および炎症性疾患の処置におけるｓ１ｐアゴニストとしての置換オキサジアゾール誘導体
ES2405054T3 (es) 2009-01-23 2013-05-30 Bristol-Myers Squibb Company Derivados de pirazol-1,2,4-oxadiazol como agonistas de esfingosina-1-fosfato
DE102009008256A1 (de) * 2009-02-10 2010-08-12 Lts Lohmann Therapie-Systeme Ag Prodrugs vom Typ N-hydroxylierter Amidine, Guanidine und/oder Aminohydrazone zur Applikation über die Haut
EP2241558A1 (de) * 2009-04-03 2010-10-20 Merck Serono SA Oxadiazolderivate
AR076984A1 (es) 2009-06-08 2011-07-20 Merck Serono Sa Derivados de pirazol oxadiazol
US20110034469A1 (en) 2009-08-04 2011-02-10 Takeda Pharmaceutical Company Limited Heterocyclic Compound
US8399451B2 (en) 2009-08-07 2013-03-19 Bristol-Myers Squibb Company Heterocyclic compounds
US9216972B2 (en) 2009-10-29 2015-12-22 Bristol-Myers Squibb Company Tricyclic heterocyclic compounds
JP5856980B2 (ja) 2010-01-27 2016-02-10 アリーナ ファーマシューティカルズ， インコーポレイテッド （Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸およびその塩の調製のためのプロセス
CN105503882B (zh) 2010-03-03 2019-07-05 艾尼纳制药公司 制备s1p1受体调节剂及其晶体形式的方法
ES2548683T3 (es) 2010-04-23 2015-10-20 Bristol-Myers Squibb Company Amidas del ácido 4-(5-isoxazolil o 5-pirrazolil-1,2,4-oxadiazol-3-il)-mandélico como agonistas de receptor de esfingosina-1-fosfato 1
US8822510B2 (en) 2010-07-20 2014-09-02 Bristol-Myers Squibb Company Substituted 3-phenyl-1,2,4-Oxadiazole compounds
EP2619190B1 (de) * 2010-09-24 2015-08-12 Bristol-Myers Squibb Company Substituierte oxadiazolverbindungen und ihre verwendung als s1p1-agonisten
EP2635573B1 (de) 2010-11-03 2014-10-01 Bristol-Myers Squibb Company Heterocyclische verbindungen als s1p1-agonisten zur behandlung von autoimmun- und gefässerkrankungen
EP2567959B1 (de) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridin-4-carbonsäureamid-derivate als kinaseinhibitoren
CA2862375A1 (en) * 2012-02-03 2013-08-08 Novartis Ag Process for preparing n-(4-cyclohexyl-3-trifluoromethyl-benzyloxy)-acetimidic acid ethyl ester
US9115054B2 (en) 2013-02-21 2015-08-25 Bristol-Myers Squibb Company Tetrahydronaphthalenyl compounds useful as sipi agonists
MA40082B1 (fr) 2014-08-20 2019-09-30 Bristol Myers Squibb Co Nouveau compose de substitution sphingosine phosphate utile traitement maladie rhumatisme
PL3242666T3 (pl) 2015-01-06 2025-02-17 Arena Pharmaceuticals, Inc. Związek do zastosowania w leczeniu dolegliwości związanych z receptorem s1p1
BR112017027656B1 (pt) 2015-06-22 2023-12-05 Arena Pharmaceuticals, Inc. Hábito cristalino de placa livre de sal de l-arginina de ácido (r)-2-(7-(4- ciclopentil-3-(trifluorometil)benzilóxi)- 1,2,3,4-tetra-hidrociclo-penta[b]indol-3- il)acético, composição farmacêutica que o compreende, seus usos e método de preparação do mesmo
KR102482825B1 (ko) 2016-09-02 2022-12-29 브리스톨-마이어스 스큅 컴퍼니 치환된 트리시클릭 헤테로시클릭 화합물
MX2019009841A (es) 2017-02-16 2020-01-30 Arena Pharm Inc Compuestos y metodos para el tratamiento de la colangitis biliar primaria.
MX2019009843A (es) 2017-02-16 2020-01-30 Arena Pharm Inc Compuestos y metodos para el tratamiento de la enfermedad inflamatoria intestinal con manifestaciones extraintestinales.
TWI829634B (zh) * 2017-04-06 2024-01-21 美商富曼西公司 殺真菌之噁二唑
US11059784B2 (en) 2017-08-09 2021-07-13 Bristol-Myers Squibb Company Oxime ether compounds
US11046646B2 (en) 2017-08-09 2021-06-29 Bristol-Myers Squibb Company Alkylphenyl compounds
CA3102136A1 (en) 2018-06-06 2019-12-12 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor
CN112955431A (zh) 2018-09-06 2021-06-11 艾尼纳制药公司 可用于治疗自身免疫性病症和炎性病症的化合物
US12606548B2 (en) 2019-10-07 2026-04-21 Fmc Corporation Fungicidal oxadiazoles
KR102215526B1 (ko) 2020-05-19 2021-02-15 브릿지테크놀러지(주) 세그먼트 연결장치를 이용한 프리캐스트 수직구 및 그 시공방법
CN116836157A (zh) * 2022-03-25 2023-10-03 星希尔生物科技(上海)有限公司 一种噁二唑衍生物及其制备方法和用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005533058A (ja) * 2002-06-17 2005-11-04 メルク　エンド　カムパニー　インコーポレーテッド Ｅｄｇ受容体アゴニストとしての１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）アゼチジン−３−カルボキシラートおよび１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）ピロリジン−３−カルボキシラート
AU2004240586A1 (en) * 2003-05-15 2004-12-02 Merck & Co., Inc. 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as S1P receptor agonists
US20070043014A1 (en) * 2003-10-01 2007-02-22 Merck & Co., Inc. 3,5-Aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists
WO2006131336A1 (en) * 2005-06-08 2006-12-14 Novartis Ag POLYCYCLIC OXADIAZOLES OR I SOXAZOLES AND THEIR USE AS SlP RECEPTOR LIGANDS

Also Published As

Publication number Publication date
EP2091950A1 (de) 2009-08-26
GB0625648D0 (en) 2007-01-31
DE602007009420D1 (de) 2010-11-04
US20100048639A1 (en) 2010-02-25
WO2008074820A1 (en) 2008-06-26
ES2352859T3 (es) 2011-02-23
EP2091950B1 (de) 2010-09-22

Similar Documents

Publication Publication Date Title
ATE482210T1 (de) Oxadiazolderivate als s1p1-rezeptor-agonisten
MY156822A (en) Indole derivatives as s1p1 receptor agonists
EA200970967A1 (ru) Оксадиазол замещенные производные индазола для применения в качестве агонистов сфингозин 1-фосфата (sip)
EA201100503A1 (ru) Глюкозидные производные и их применения
MX384206B (es) Formulaciones de inhibidores de dpp iv
EA200870475A1 (ru) Ингибиторы 11-бета-гидроксистероид-дегидрогеназы типа 1
EA200870472A1 (ru) Ингибиторы 11-бета-гидроксистероид-дегидрогеназы типа 1
EA200901133A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
MX2010005861A (es) Agonistas novedosos de los receptores de glucocorticoides.
DE602007010781D1 (de) N- (phenylmethyl) -2- (1h-pyrazol-4-yl) acetamid-derivate als p2x7-antagonisten zur behandlung von schmerzen, entzündungen und neurodegeneration
EA201070327A1 (ru) Катехоламиновые производные и их пролекарства
EA200970302A1 (ru) Тиофенпиразолопиримидиновые соединения
EA200801997A1 (ru) Новые соединения
GEP20135744B (en) Quinuclidine carbonate derivatives and medicinal compositions containing the same
TW200637874A (en) Peptides with neuropeptide-2 receptor (Y2R) agonist activity
EA200970065A1 (ru) Производные пиперазинила, предназначенные для лечения заболеваний, опосредованных рецептором gpr38
ATE542795T1 (de) Benzylpiperazinderivate als motilin- rezeptorantagonisten
TW200740814A (en) Compounds
TW200745122A (en) New compounds I
MEP1008A (xx) 3-aminociklopentankarboksamidi kao modulatori receptora hemokina
MY157425A (en) Substituted oxindole derivatives and the use thereof for the treatment of vasopressin-dependent illnesses
MX2008002805A (es) Derivados de carboxamida como antagonistas del receptor muscarinico.
DE602006018713D1 (de) Als agonisten für den nikotinischen acetylcholinrezeptor geeignete azabicycloalkanderivate
EA201100502A1 (ru) Гликозидные производные и их применения
ATE474834T1 (de) Als agonisten des gpr38-rezeptors geeignete biarylverbindungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties